Genexus – A Major Step Forward in Diagnostic NGS

Presented past: Michael Hummel

Speaker Biography: Prof. Dr Michael Hummel is head of the molecular diagnostics at the Institute of Pathology (Charité, Berlin) and a longstanding researcher with a scientific topic for molecular mechanisms in malignant lymphoma (more than 350 high ranking publications). Molecular diagnostics at Charité covers a broad spectrum of assays ranging from simple PCRs for the detection of viral and bacterial infections, complex PCRs for B- and T-jail cell clonality, RT-PCR based gene expression for chest cancer, FISH for chromosomal alterations and targeted NGS (started in June 2014) for mutation analysis in cancer tissues and liquid biopsies.

Webinar: Genexus – A Major Step Forward in Diagnostic NGS

Webinar Abstract: NGS is still perceived as a complex, hard to implement and validate method that requires highly experienced people. Outsourcing next-generation sequencing (NGS) testing could live an option to overcome these limitations but it might end up existence very expensive, and stringent sample requirements often lead to results existence of poor quality and inconclusive. Recent clinical research studies show this issue effects roughly 20% of patients, excluding samples not submitted because they failed to meet sample quantity criteria.